Misonix Announces Presentation at Leading Spine Surgery Conference Promoting the BoneScalpel™ in Deformity Procedures

FARMINGDALE, N.Y., June 23, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, announced today that the BoneScalpel was featured in a presentation at the Spine Technology and Educational Group Organization's (STEGO) "State of Spine Surgery: A Think Tank" meeting held June 18 - 20, 2015 in Los Cabos, Mexico.

The BoneScalpel is an ultrasonic bone-cutting instrument that provides a clean, controlled bone incision and removal that is also soft-tissue sparing.  The BoneScalpel is used in many different surgical procedures, including spine. 

Gregory M. Mundis, Jr., MD, an orthopedic surgeon practicing at the San Diego Center for Spinal Disorders, San Diego, CA, presented The Use of an Ultrasonic BoneScalpel in the Treatment of Spinal Deformity to an audience of spine surgeons on Friday, June 19, 2015.  Dr. Mundis said, "The BoneScalpel is a mainstay in my deformity surgery practice as it offers greater efficiencies, less blood loss and a safer procedure than traditional instruments."

"The STEGO audience appeared very interested and engaged with learning about the BoneScalpel technology.  For those in attendance, several surgeons have already incorporated BoneScalpel into their practice, yet many more appeared anxious to evaluate the technology for themselves," he added.

"We are encouraged by the rapidly growing number of surgeons who use the BoneScalpel everyday around the world.  Presentations at important meetings, such as this one, are instrumental in generating awareness and expanding the user base for the BoneScalpel amongst the global spine surgeon community," said Michael A. McManus, Jr., president and chief executive officer of Misonix.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.

Related Links

http://www.misonix.com